Forward Looking Statements 2 This document contains forward-looking statements, as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, about Ignyta, Inc. (the “Company”). Statements that are not purely historical are forward-looking statements. These include statements regarding, among other things: our novel technologies and methods; our ability to leverage our technology platform in the development of RXDX-101, RXDX-102 and other potential product candidates; our ability to design and conduct development activities and preclinical and clinical studies and trials for our potential product candidates; the potential results of any preclinical or clinical studies or trials we may conduct; and our ability to obtain regulatory approvals in order to market any of our product candidates. Forward looking statements involve known and unknown risks that relate to future events or the Company’s future financial performance, some of which may be beyond the Company’s control, and the actual results could differ materially from those discussed in this document. Accordingly, the Company cautions investors not to place undue reliance on the forward-looking statements contained in, or made in connection with, this document. Such risks include, among others, the Company’s ability to initiate and complete clinical trials, the potential advantages of the Company’s product candidates and the Company’s capital needs. The identification and development of the Company’s product candidates and the projected commencement and completion of the Company’s clinical trials may be affected by difficulties or delays. In addition, the Company’s results may be affected by its ability to manage its financial resources, difficulties or delays in developing manufacturing processes for its product candidates, preclinical and toxicology testing and regulatory developments. Delays in clinical programs, whether caused by competitive developments, adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company’s financial position and prospects. Prior clinical trial program designs and results are not necessarily predictive of future clinical trial designs or results. If the Company’s product candidates do not meet safety or efficacy endpoints in clinical evaluations, they will not receive regulatory approval and the Company will not be able to market them. The Company may not be able to enter into any strategic licensing or partnership agreements or secure product candidates from third parties when needed or desired. Operating expense and cash flow projections involve a high degree of uncertainty, including variances in future spending rates due to changes in corporate priorities, the timing and outcomes of clinical trials, competitive developments and the impact on expenditures and available capital from licensing and strategic collaboration opportunities. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. The Company is at an early stage of development and may not ever have any products that generate significant, or any, revenue. The Company has a history of losses during its short operating history and may never be profitable. The forward-looking statements contained in this document represent the Company’s estimates and assumptions only as of the date of this document and the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this document as a result of new information, future events or changes in the Company’s expectations. Investing in the Company involves a high degree of risk, including, among others, those described above. Investors must rely upon their own examination of the Company, including the merits and risks involved. Investors should consult all of the information, including the risk factor disclosures, set forth in the reports and other documents the Company files with the Securities and Exchange Commission, available at www.sec.gov, including without limitation the Company’s Current Report on Form 8-K/A dated December 9, 2013. Third-party information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, and should not be construed as a representation by, the Company. | 
